GlobeNewswire
Dublin, Feb. 26, 2021 (GLOBE NEWSWIRE) -- The "Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global systemic scleroderma treatment market expected to reach USD 2.09 billion by 2028, according to the study.The global market for systemic scleroderma treatment is anticipated to grow due to presence of innovative small molecule therapies, significant government backed funding, and increasing clinical trials for the concerned diseases. Moreover, the presence industry-academia collaborations in the developed countries are favoring the systemic scleroderma treatment industry growth.The global market for systemic scleroderma treatment is fragmented based on drug class and region. The drug class market segment has been bifurcated into immuno-suppressors, phosphodiesterase 5 inhibitors-PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, and others. The systemic scleroderma treatment industry region segment has been bifurcated into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.Segment Highlights Immunosuppressors market segment accounted for over 60% of the overall market revenue share in 2020 and is expected to continue its dominance in systemic scleroderma treatment industry over the forecast period owing to higher efficiency and comparatively improved results.North America systemic scleroderma treatment industry is dominating the global market for systemic scleroderma treatment, holding over 40% of the market share throughout forecast period. Favorable reimbursement scenario and strong drug pipeline favoring the systemic scleroderma treatment industry growth.The market players including Roche Ltd.; United Therapeutics; Boehringer Ingelheim International GmbH together held a significant market share of global market for systemic scleroderma treatment in year 2020. Key Topics Covered: 1. Introduction1.1. Report Description1.1.1. Objectives of the Study1.1.2. Market Scope1.1.3. Assumptions1.2. Stakeholders2. Executive Summary2.1. Market Highlights3. Research Methodology3.1. Overview3.1.1. Data Mining3.2. Data Sources3.2.1. Primary Sources3.2.2. Secondary Sources4. Systemic Scleroderma Treatment Market Insights4.1. Systemic Scleroderma Treatment - Industry snapshot4.2. Systemic Scleroderma Treatment Market Dynamics4.2.1. Drivers and Opportunities4.2.1.1. Emergence of innovative therapies4.2.1.2. Rising prevalence of rare diseases4.2.2. Restraints and Challenges4.2.2.1. Lack of clinical evidence4.3. Porter's Five Forces Analysis4.3.1. Bargaining Power of Suppliers (Moderate)4.3.2. Threats of New Entrants: (Low)4.3.3. Bargaining Power of Buyers (Moderate)4.3.4. Threat of Substitute (Moderate)4.3.5. Rivalry among existing firms (High)4.4. PESTLE Analysis4.5. Systemic Scleroderma Treatment Market Industry trends5. Global Systemic Scleroderma Treatment Market, by Drug Class5.1. Key Findings5.2. Introduction5.2.1. Global Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)5.3. Immuno-suppressors5.3.1. Global Systemic Scleroderma Treatment Market, by Immuno-suppressors, By Region, 2016-2028 (USD Million)5.4. Phosphodiesterase 5 inhibitors-PHA5.4.1. Global Systemic Scleroderma Treatment Market, by Phosphodiesterase 5 inhibitors-PHA, by Region, 2016-2028 (USD Million)5.5. Endothelin Receptor Antagonists5.5.1. Global Systemic Scleroderma Treatment Market, by Endothelin Receptor Antagonists, by Region, 2016-2028 (USD Million)5.6. Prostacyclin Analogues5.6.1. Global Systemic Scleroderma Treatment Market, by Prostacyclin Analogues, by Region, 2016-2028 (USD Million)5.7. Calcium Channel Blockers5.7.1. Global Systemic Scleroderma Treatment Market, by Calcium Channel Blockers, by Region, 2016-2028 (USD Million)5.8. Others5.8.1. Global Systemic Scleroderma Treatment Market, by Others, by Region, 2016-2028 (USD Million)6. Systemic Scleroderma Treatment Market Assessment by Geography6.1. Key findings6.2. Introduction6.2.1. Systemic Scleroderma Treatment Market Assessment, By Geography, 2016-2028 (USD Million)6.3. Systemic Scleroderma Treatment Market - North America6.3.1. North America: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.3.2. Systemic Scleroderma Treatment Market - U.S.6.3.2.1. U.S.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.3.3. Systemic Scleroderma Treatment Market - Canada6.3.3.1. Canada.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4. Systemic Scleroderma Treatment Market - Europe6.4.1. Europe: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.2. Systemic Scleroderma Treatment Market - UK6.4.2.1. UK: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.3. Systemic Scleroderma Treatment Market - France6.4.3.1. France: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.4. Systemic Scleroderma Treatment Market - Germany6.4.4.1. Germany: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.5. Systemic Scleroderma Treatment Market - Italy6.4.5.1. Italy: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.6. Systemic Scleroderma Treatment Market - Spain6.4.6.1. Spain: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.7. Systemic Scleroderma Treatment Market - Netherlands6.4.7.1. Netherlands: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.4.8. Systemic Scleroderma Treatment Market - Austria6.4.8.1. Austria: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5. Systemic Scleroderma Treatment Market - Asia-Pacific6.5.1. Asia Pacific: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5.2. Systemic Scleroderma Treatment Market - China6.5.2.1. China: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5.3. Systemic Scleroderma Treatment Market - India6.5.3.1. India.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5.4. Systemic Scleroderma Treatment Market - Malaysia6.5.4.1. Malaysia: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5.5. Systemic Scleroderma Treatment Market - Japan6.5.5.1. Japan: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5.6. Systemic Scleroderma Treatment Market - Indonesia6.5.6.1. Indonesia: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.5.7. Systemic Scleroderma Treatment Market - South Korea6.5.7.1. South Korea.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.6. Systemic Scleroderma Treatment Market - Middle East & Africa6.6.1. Middle East & Africa.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.6.2. Systemic Scleroderma Treatment Market - Saudi Arabia6.6.2.1. Saudi Arabia.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.6.3. Systemic Scleroderma Treatment Market - UAE6.6.3.1. UAE: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.6.4. Systemic Scleroderma Treatment Market - Israel6.6.4.1. Israel: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.6.5. Systemic Scleroderma Treatment Market - South Africa6.6.5.1. South Africa: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.7. Systemic Scleroderma Treatment Market - Latin America6.7.1. Latin America: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.7.2. Systemic Scleroderma Treatment Market - Mexico6.7.2.1. Mexico.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.7.3. Systemic Scleroderma Treatment Market - Brazil6.7.3.1. Brazil.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)6.7.4. Systemic Scleroderma Treatment Market - Argentina6.7.4.1. Argentina.: Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)7. Competitive Landscape7.1. Expansion and Acquisition Analysis7.1.1. Expansion7.2. Partnerships/Collaborations/Agreements/Exhibitions8. Company Profiles8.1. F. Hoffman La Roche Ltd.8.1.1. Company Overview8.1.2. Financial Performance8.1.3. Drug Class Benchmarking8.1.4. Recent Developments8.2. Johnson & Johnson Services, Inc.8.2.1. Company Overview8.2.2. Financial Performance8.2.3. Drug Class Benchmarking8.2.4. Recent Developments8.3. United Therapeutics Corporation8.3.1. Company Overview8.3.2. Financial Performance8.3.3. Drug Class Benchmarking8.3.4. Recent Developments8.4. Boehringer Ingelheim International GmbH8.4.1. Company Overview8.4.2. Financial Performance8.4.3. Drug Class Benchmarking8.4.4. Recent Developments8.5. Novartis AG8.5.1. Company Overview8.5.2. Financial Performance8.5.3. Drug Class Benchmarking8.5.4. Recent Developments8.6. GlaxoSmithKline plc.8.6.1. Company Overview8.6.2. Financial Performance8.6.3. Drug Class Benchmarking8.6.4. Recent Developments8.7. Eli Lilly and Company8.7.1. Company Overview8.7.2. Financial Performance8.7.3. Drug Class Benchmarking8.7.4. Recent Developments8.8. Bayer AG8.8.1. Company Overview8.8.2. Financial Performance8.8.3. Drug Class Benchmarking8.8.4. Recent Developments8.9. Teva Pharmaceutical Industries Ltd.8.9.1. Company Overview8.9.2. Financial Performance8.9.3. Drug Class Benchmarking8.9.4. Recent Developments8.10. Gilead Sciences Inc.8.10.1. Company Overview8.10.2. Financial Performance8.10.3. Drug Class Benchmarking8.10.4. Recent Developments8.11. Pfizer Inc.8.11.1. Company Overview8.11.2. Financial Performance8.11.3. Drug Class Benchmarking8.11.4. Recent Developments8.12. Mylan N.V.8.12.1. Company Overview8.12.2. Financial Performance8.12.3. Drug Class Benchmarking8.12.4. Recent DevelopmentsFor more information about this report visit https://www.researchandmarkets.com/r/qettlh CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900